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Abstract
Background: Clostridium difficile infection (CDI) is a common cause of diarrhoea in hospitalised patients. Around
the world, the incidence and severity of CDI appears to be increasing, particularly in the northern hemisphere. The
purpose of this integrative review was to investigate and describe mortality in hospitalised patients with CDI.
Methods: A search of the literature between 1 January 2005 and 30 April 2011 focusing on mortality and CDI in
hospitalised patients was conducted using electronic databases. Papers were reviewed and analysed individually
and themes were combined using integrative methods.
Results: All cause mortality at 30 days varied from 9% to 38%. Three studies report attributable mortality at 30 days,
varying from 5.7% to 6.9%. In hospital mortality ranged from 8% to 37.2%
Conclusion: All cause 30 day mortality appeared to be high, with 15 studies indicating a mortality of 15% or
greater. Findings support the notion that CDI is a serious infection and measures to prevent and control CDI are
needed. Future studies investigating the mortality of CDI in settings outside of Europe and North America are
needed. Similarly, future studies should include data on patient co-morbidities.
Keywords: Clostridium difficile infection, Clostridium difficile associated diarrhoea, Mortality, Death
Background
The spectrum of diseases caused by Clostridium difficile
ranges from uncomplicated diarrhoea to pseudomem-
branous colitis and toxic megacolon, and is often termed
‘Clostridium difficile-associated diarrhoea’ or ‘Clostridium
difficile infection’ (CDI) [1-4]. Around the world, the inci-
dence and severity of CDI has increased, particularly in
the northern hemisphere [5]. This increase appears to be
driven by a number of factors, including large outbreaks
of CDI in hospitals, a change in circulating strains of C.
difficile, and factors such as inappropriate antibiotic usage
and poor standards of environmental cleanliness [6-10].
This paper presents a review of studies that have investi-
gated mortality and CDI in hospitalised patients.
Methods
Design
An integrative review design was used. An integrative
design was chosen because it summarises empirical and
theoretical literature and allows for the synthesis of
results when study designs and methodologies vary be-
tween studies. As a result, it provides a more compre-
hensive understanding of a particular issue [11].
Search Methods
The literature was accessed through searches on two
electronic databases—Medline and Pubmed—limited to
the period 1 January 2005 to 30 April 2011. This limita-
tion reflects the recently changing epidemiology of CDI.
Other limits included only searching literature published
in English, and studies involving humans. Key search
words used were ‘Clostridium difficile and mortality’ and
‘Clostridium difficile and death’. These searches were
combined, with duplicate studies removed.
The next step of the search strategy process involved a
preliminary review of the articles. Only prospective or
retrospective articles that were case controlled, cohort
or reviews were included. Additionally, articles were only
included if they examined the mortality of hospitalised
patients and were not limited to CDI in a specific patient
group, for example, a person with cancer. Only articles
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that did not use CDI as a comparison group were
included, for example, mild versus severe CDI and
related mortality. The rationale for excluding such arti-
cles was to gain a better understanding of CDI in the
general hospitalised population rather than those with a
specific illness.
A second review of the articles was undertaken, and
this step excluded articles that did not examine mortality
at fixed intervals, for example, 30 or 90 days. The inclu-
sion of studies that documented mortality at fixed inter-
vals was chosen in an attempt to assist the pooling of
data during data analysis.
Search Outcome
The initial search yielded 362 articles. Following the first re-
view, 303 articles were excluded and 59 articles remained.
The second review, which excluded articles that did not
examine CDI mortality at fixed intervals, resulted in a fur-
ther exclusion of 23 articles. A total of 26 articles remained
after the second review. Figure 1 provides a summary of the
search strategy process.
Quality Appraisal
All papers included in this review were published in
peer-reviewed journals.
Data abstraction and synthesis
All articles were analysed sequentially. The author, year,
purpose, study design, data collection and analysis were
reviewed. Data on mortality at fixed intervals were
extracted from the studies and a table was populated (see
Table 1).
Results
Study Characteristics
Of the 24 articles included, 12 were prospective, 11 retro-
spective and one was a review. Eighteen studies reported
mortality at 30 days or less, with 12 studies reporting mor-
tality at further endpoints, predominantly 90 or 180 days.
One study that reported 30-day mortality used 30-day
post-discharge as the definition [12]. The choice of 30 days
post-discharge as the method used to examine mortality
was made due to limitations in available data, which
should be noted when considering results from this study.
Four studies examined in-hospital mortality in addition to
30-day mortality. The reported mortality in each of these
studies is detailed in Table 1 and is explored in more detail
later.
The search strategy used to identify articles for this re-
view did not identify the same articles in the review pub-
lished by Karas, Enoch & Aliyu (2010). Seven articles
included in the review by Karas, Enoch and Aliyu [13]
were not include in our review. These studies did not
meet our inclusion criteria and were excluded if the par-
ticipants were from a selected group. For example, they
had a specific strain of CDI or had severe CDI. Con-
versely, our study did identify and included 14 studies
not used by Karas, Enoch and Aliyu [13]. The primary
reason for this discrepancy was the recent publications
of studies, with 11 of these 14 published in the past two
years. The review by Karas, Enoch and Aliyu [13], also
focussed on attributable mortality.
Reported mortality
As reported in the included studies, mortality varied
considerably, both in the type of mortality calculated
and the figures represented. The study design, exclusion
criteria of participants and the data collected in the stud-
ies varied, making the pooling of data for analysis impos-
sible. All-cause mortality at 30 days varied from 9% to
38%, as shown in Table 1. Three studies reported all-
cause mortality at 90 days, with a range of 27% to 30%
[14-16]. Similarly, three studies report attributable mor-
tality at 30 days, varying from 5.7% to 6.9% [17-19]. In-
hospital mortality was reported in four studies and ran-
ged from 8% to 37% [20-23].
Eighteen studies documented all-cause mortality at
30 days, or 28 days in the case of the study undertaken by
Sundram et al. [24], which examined two strains of C.diffi-
cile (027 and 106) and their respective mortality. The total
cohort size was larger than the two groups combined;
therefore, it was unclear whether participants with other
strains of C.difficile died. Acknowledging the limitations of
different study designs, and excluding the study under-
taken by Sundram et al. [24], 2,041 of 7,774 persons
(26.3%) died within 30 days of CDI diagnosis. These
figures include people identified with CDI in these studies
Figure 1 Summary of search strategy. Notes. 1 Articles were
excluded if they were not case controlled, cohort or reviews or did
not examine mortality in hospitalised patients. 2 Articles were
excluded if they did not examine mortality at fixed intervals.
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Table 1 Summary of reported mortality from literature
Author Study type Country 30-day mortality Mortality at
endpoint (other)
Participants
Arvand, Hauri, Zaiss, Witte
& Bettge-Weller (2009)
Prospective
multicentre
Germany 25% - 41
Bhangu, Bhangu, Nightingale
& Michael (2010)
Cohort UK 38% - 158
Bishara, Peled, Pitlik
& Samra (2008)
Case control Israel 15% case - Total 217
11.5% control (NS) 52 cases
Cadena et al. (2010) Cohort US 16% 29% at 90 days 129
Chung et al. (2010) Cohort Taiwan 23.3% 37.2% IHM 86
Cloud, Noddin, Pressman,
Hu & Kelly (2009)
Cohort US - 12.1% IHM 272
Dubberke et al. (2008) Case control US - 38% cases
at 180 days
Cohort =
18,050 390
cases
12% non-cases
at 180 days
Fenner et al. (2008) Cohort Switzerland 9% -
78 cases
Gasperino et al. (2010) Cohort US 16% cases,
5% controls
20% cases
IHM (cases)
216,108 cases
8% IHM
(controls)
Gravel et al. (2009) Prospective
multicentre
Canada 16.3% - 1430
5.7% attributable
Gulihar, Nixon, Jenkins
& Taylor (2009)
Cohort UK 19% (cases) 67% cases
at 180 days
170 cases
9% match cohort 29% matched
cohort at 180 days
3,247 matches
Karas, Enoch & Aliyu (2010) Review UK Not applicable Not applicable Not applicable
Kenneally et al. (2007) Cohort US 36.7% - 278
6.1% attributable
Labbe et al. (2008) Cohort Canada 23.9% - 230
Loo et al. (2005) Prospective
multicentre
Canada 24.8% - 1703
6.9% attributable
Lyytikainen et al. (2009) Cohort Finland - 14% at 30 days
post-discharge
8 093
Marra, Edmond, Wenzel
& Bearman (2007)
Cohort US 17.2% at 14 days 58
27.6% IHM
McGowan et al. (2011) Cohort UK 35.5% 13.4% at 7 days 2,571
20% at 14 days
58.7% at 1 year
Musher et al. (2005) Prospective
observational
US - 27% at 90 days 207
Pant et al. (2010) Cohort US 13.6% - 184
Cohort UK 24.7% 30.0% at 90 days 227
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who died within 30 days (all-cause mortality) [14,15,17-
20,22,25-34].
The manner in which mortality was analysed and pre-
sented in the studies differed; however, there were some
similarities. In several studies, participants were divided
into those with CDI and those without [19,22,27,35].
Other studies divided participants into two groups: survi-
vors and non-survivors [18,26,33]. Regardless of the meth-
ods used, similar data analysis involved using mortality at
a fixed period. Commonly, X2, or Fisher’s exact test, was
used for categorical data analysis, while a t test was used
for continuous variables [14,20]. Kaplan–Meier survival
analysis and regression model were used in some studies
[18,23,28,30,32,33]. Not all studies undertook adjustment
for variables when determining mortality rates. Despite
collecting basic demographic data on cases, Charlson co-
morbidity data and exposure to recent medication such as
antimicrobials, the study undertaken by Chung et al. [20]
did not adjust for any variables in the calculation of hos-
pital mortality and all-cause mortality.
In addition to studies comparing survivors and non-
survivors, or those with and without CDI, some studies
examined mortality by age group [17,31,34]. In the retro-
spective cohort study undertaken by McGowan et al. [31],
age groups were divided into decades, with those under
the age of 40 years grouped together. A significant differ-
ence in 30-day mortality was found for the three groups
aged over 60 years, using <60 yeardsas the reference
group (X2 = 65.82; df: 2; P< 0.05). The study did not
examine the effect of co-morbidity on outcome [31]. Simi-
lar to the work of McGowan et al. [31], a prospective
multi-centred study of 1,430 participants demonstrated
that age-specific mortality increased sharply after 60 years
of age [17]. These two studies demonstrate the importance
of collecting and analysing age-related data.
Some studies presented data that compared groups based
on the causative strain of C.difficile [24,30,31]. The retro-
spective cohort study undertaken by Labbe et al. [30] found
that patients affected by C.difficile ribotype 027 were twice
as likely to die within 30 days of diagnosis than patients
infected with other ribotypes. Similar results were demon-
strated in a prospective case-controlled study comparing
persons with CDI caused by ribotype 027, 106 and all other
ribotypes [24].
Discussion
The majority of studies identified in this review were
undertaken in the United States (nine), United Kingdom
(seven) or Canada (three). No studies were included from
an Asian or Asian Pacific setting. As there are different
circulating strains of CDI in different countries, this is an
important issue because mortality for persons with CDI in
different regions may vary. A higher incidence of CDI
compared to other countries with data on CDI incidence,
coupled with an increased focus on CDI due to high-
profile hospital outbreaks, may provide some insights into
the number of included articles from these countries.
The majority of studies used the identification of toxins
A or B via EIA or ELISA as part of the case definition of
CDI. However, there were variations in which faecal sam-
ples were tested for C.difficile. The effect of such varia-
tions on reported mortality remains unknown. However, it
would be logical to assume that a less sensitive laboratory
detection approach may identify fewer cases in a given
population. This has the potential to underestimate the in-
cidence of CDI and, thus, the total number of people who
died after having CDI. The argument for a standardised
testing approach for CDI has previously been made [36].
A co-morbidity score, such as the Charlson co-morbidity
index, was collected in a limited number of studies [18-
21,23,30,33,35]. A number of studies used other tools such
as the American Society of Anaesthesiologists (ASA) grade
or Acute Physiology and Chronic Health Evaluation (APA-
CHE) II, while a number of studies collected data on co-
morbidities but did not specify how or why they chose
those co-morbidities [14,17,24,27,28,34,37]). The admitting
diagnosis was collected for two studies [19,23]. The vari-
ation in the use of co-morbidity data makes comparisons
between studies challenging and potentially limits the valid-
ity of results. Where co-morbidities were collected, they
Table 1 Summary of reported mortality from literature (Continued)
Shears, Prtak
& Duckworth (2010)
Sundram et al. (2009) Case control UK 14.4% at 28 days
(extrapolated)
11% at 3 days (027) 97 cases
3% at 3 days (106) 97 controls
Wilson et al. (2010) Cohort UK 35.9% - 128
Zilberberg, Shorr,
Micek, Doherty
& Kollef (2009)
Cohort. Secondary
analysis of
Kenneally et al.
(2007)
US 26.9% <65 years - 278
45.2% >65
Note. IHM = in-hospital mortality.
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were shown to influence mortality in patients with CDI
[18,27]. In one instance where co-morbidity data were not
collected, the researchers recognised this limitation and
suggested that this area be included in future research [31].
The manner in which data were collected about drug
therapy, surgery and nasogastric tube exposure were not
reported consistently, with different periods and a range of
procedures used. Further, in these studies, mortality was
one outcome being examined alongside other variables
such as risk factors for CDI. If a study was to examine
CDI mortality as the single outcome, then the usefulness
of including data on some of the data described above
could be limited, particularly as there is no standardised
method or definition used.
Conclusion
There was limited homogeneity between the studies
included in this review. Differences in study design, patient
groups and data collected from participants were found.
Some studies lacked demographic and co-morbidity data,
which is a similar finding to the review undertaken by
Karas, Enoch and Aliyu [13]. In general, all-cause 30-day
mortality appeared to be high, with 15 studies indicating a
mortality of 15% or more. Several studies demonstrated that
increased age was a risk factor for mortality, indicating the
need to include and analyse such data in future studies.
No articles from an Asian or Asian Pacific setting were
included in this review. Even accepting all-cause mortality
at the low end of the included studies in this review, CDI
clearly have a significant effect on hospitalised patients.
Studies investigating the mortality of CDI in settings out-
side of Europe and North America are needed so that the
epidemiology of CDI in these regions can be understood.
Future studies examining the mortality of CDI should in-
clude basic demographic data, reporting of mortality at seven
days, 30 days and 90 days after the first diagnosis of the CDI,
the use of exclusion criteria and acquisition definitions as
recommended in the international literature. In addition, the
studies should use a co-morbidity index score such as the
Charlson co-morbidity index. In doing so, pooling data
becomes possible and comparisons between studies become
easier. Similarly, the addition of data on antibiotic exposure
will assist future meta-analysis on the role of antibiotics in
CDI. The recommendations posed for future studies are
similar to those described by Karas, Enoch and Aliyu [13] in
the only review article identified. This review supports the
notion that measures to prevent CDI are needed, given its
impact on mortality.
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